REGENXBIO Inc. (RGNX)
NASDAQ: RGNX · Real-Time Price · USD
7.85
-0.05 (-0.63%)
Aug 8, 2025, 4:00 PM - Market closed
Splunk Revenue
REGENXBIO had revenue of $21.36M in the quarter ending June 30, 2025, a decrease of -4.20%. This brings the company's revenue in the last twelve months to $155.78M, up 74.95% year-over-year. In the year 2024, REGENXBIO had annual revenue of $83.33M, down -7.66%.
Revenue (ttm)
$155.78M
Revenue Growth
+74.95%
P/S Ratio
2.58
Revenue / Employee
$441,309
Employees
353
Market Cap
396.54M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 83.33M | -6.91M | -7.66% |
| Dec 31, 2023 | 90.24M | -22.48M | -19.94% |
| Dec 31, 2022 | 112.72M | -357.62M | -76.03% |
| Dec 31, 2021 | 470.35M | 315.78M | 204.30% |
| Dec 31, 2020 | 154.57M | 119.33M | 338.70% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 422.82B |
| Johnson & Johnson | 90.63B |
| Merck & Co. | 63.62B |
| AbbVie | 58.33B |
| AstraZeneca | 56.50B |
| Novartis AG | 55.19B |
| Eli Lilly and Company | 53.26B |
| Novo Nordisk | 49.11B |
RGNX News
- 1 day ago - REGENXBIO Inc. (RGNX) Q2 2025 Earnings Call Transcript - Seeking Alpha
- 2 days ago - REGENXBIO Reports Second Quarter 2025 Financial Results and Operational Highlights - PRNewsWire
- 2 days ago - REGENXBIO Announces Pivotal Program for Surabgene Lomparvovec in Diabetic Retinopathy - PRNewsWire
- 9 days ago - REGENXBIO to Host Conference Call on August 7 to Discuss Second Quarter 2025 Financial Results and Operational Highlights - PRNewsWire
- 4 weeks ago - REGENXBIO Announces Publication of Preclinical Results Demonstrating Functional Benefits of Novel Microdystrophin Construct in RGX-202 Investigational Gene Therapy for Duchenne Muscular Dystrophy - PRNewsWire
- 2 months ago - Regenxbio's RGX-121 Could Become The New Standard Of Care In Hunter Syndrome - Seeking Alpha
- 2 months ago - Early Wins: RegenXBio's Gene Therapy Helps Duchenne Patients Walk Stronger, Longer - Benzinga
- 2 months ago - REGENXBIO REPORTS NEW POSITIVE FUNCTIONAL DATA FROM PHASE I/II AFFINITY DUCHENNE® TRIAL OF RGX-202 - PRNewsWire